In Vitro: Natural Compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) Against Sars-Cov2 Strain Isolated from Egypt

Background: The current pandemic of the coronavirus disease-2019 (COVID-19) has badly affected our life during the year 2020. SARS-CoV-2 is the primary causative agent of the newly emerged pandemic. Natural flavonoids, Terpenoid and Thymoquinone are tested against different viral and host-cell protein targets. These natural compounds have a good history in treating Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV).

Methods: Molecular docking combined with cytotoxicity and plaque reduction assay is used to test the natural compounds against different viral (Spike, RdRp, and Mpro) and host-cell (TMPRSS II, keap 1, and ACE2) targets.

Results: The results demonstrate the binding possibility of the natural compounds (Thymol, Carvacrol, Hesperidine, and Thymoquinone) to the viral main protease (Mpro). Some of these natural compounds were approved to start clinical trail from Egypt Center for Research and Regenerative Medicine ECRRM IRB (Certificate No. IRB00012517)

Conclusion: Development of an effective anti-viral for SARSCoV- 2 could help to limit the viral load. Benchmarking testing of those natural compounds against other potential antivirals for SARS-CoV-2 with alternative mechanisms of action would thus be important as soon as practicable.

Author(s): Mohamed G. Seadawy1*, Ahmed F. Gad1 , Mohamed Shamel1 , Bassem Elharty1 , Mostfa F. Mohamed1 , Sherine Helmy2 , Abdo A. Elfiky3 , Aya Ahmed4 , Abdel Rahman N. Zekri4

Abstract | Full-Text | PDF

Share This Article
17+ Million Readerbase
Recommended Conferences
Google Scholar citation report
Citations : 1

Clinical Immunology and Infectious Diseases received 1 citations as per Google Scholar report

Abstracted/Indexed in
  • Google Scholar

View More »

Flyer image